Role of pharmacogenomics in the management of traditional and novel oral anticoagulants

Pharmacotherapy

Volumn 31, Issue 12, 2011, Pages 1192-1207

  Cavallari, Larisa H ^a   Shin, Jaekyu ^b   Perera, Minoli A ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

CYP2C9 gene; Cytochrome P450; Dabigatran; Genotype; Pharmacogenetics; Polymorphism; Vitamin K epoxide reductase complex subunit 1; VKORC1 gene; Warfarin

Indexed keywords

DABIGATRAN; RIVAROXABAN; WARFARIN;

AMINO ACID SUBSTITUTION; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CYP4F2 GENE; CYTOCHROME P450 2C9 GENE; DOSE CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG RESPONSE; ETHNICITY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; MUTATOR GENE; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PRACTICE GUIDELINE; RACE DIFFERENCE; REIMBURSEMENT; REVIEW; THROMBOEMBOLISM; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1 GENE;

ADMINISTRATION, ORAL; ALGORITHMS; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC TESTING; GENOTYPE; HUMANS; PHARMACOGENETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WARFARIN;

EID: 83055174032     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.12.1192     Document Type: Review

References (101)

1. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009;113:784-92.
2. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902. (Pubitemid 24179151)
3. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26. (Pubitemid 37087616)
4. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest 2008;133:S160-98.
5. Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009;20:912-21.
6. Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010;56:823-31.
7. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-64.
8. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008;84:326-31.
9. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 1997;7:203-10. (Pubitemid 27290634)
10. Ieiri I, Tainaka H, Morita T, et al. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther Drug Monit 2000;22:237-44. (Pubitemid 30346437)
11. Limdi NA, Arnett DK, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 2008;9:511-26. (Pubitemid 351803913)
12. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010;115:3827-34.
13. Cavallari LH, Langaee TY, Momary KM, et al. Genetic and clinical predictors of warfarin dose requirements in African-Americans. Clin Pharmacol Ther 2010;87:459-64.
14. National Center for Biotechnology Information, National Library of Medicine. Database of single nucleotide polymorphisms (dbSNP). Bethesda, MD. dbSNP accession: ss69088153, ss13761958, ss3027906, ss2494699, ss105440151 (dbSNP build ID:132). Available from http://www.ncbi.nlm. nih.gov/SNP/. Accessed September 22, 2011.
15. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9*8 is prevalent among African- Americans: implications for pharmacogenetic dosing. Pharmacogenomics 2009;10:1243-55.
16. Dickmann LJ, Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African-Americans. Mol Pharmacol 2001;60:382-7. (Pubitemid 32678304)
17. Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 2005;15:779-86. (Pubitemid 41531727)
18. Blaisdell J, Jorge-Nebert LF, Coulter S, et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004;14:527-37. (Pubitemid 39106854)
19. Wester MR, Yano JK, Schoch GA, et al. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-a resolution. J Biol Chem 2004;279:35630-7. (Pubitemid 39100565)
20. Wei L, Locuson CW, Tracy TS. Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity. Mol Pharmacol 2007;72:1280-8. (Pubitemid 350012601)
21. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002;72:702-10. (Pubitemid 36021009)
22. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998;63:519-28. (Pubitemid 28277273)
23. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements: a systematic review and meta-analysis. Eur J Clin Pharmacol 2009;65:365-75.
24. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-8. (Pubitemid 34289221)
25. Perera MA, Gamazon E, Cavallari LH, et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African-Americans. Clin Pharmacol Ther 2011;89:408-15.
26. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004;427:537-41. (Pubitemid 38209110)
27. Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 2008;82:495-500.
28. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:645-9. (Pubitemid 40070748)
29. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93. (Pubitemid 40740552)
30. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008;112:1013-21.
31. McDonald MG, Rieder MJ, Nakano M, Hsia CH, Rettie AE. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 2009;75:1337-46.
32. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008;111:4106-12.
33. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose [online exclusive article]. PLoS Genet 2009;5:e1000433. Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652833/?tool=pubmed.
34. Pautas E, Moreau C, Gouin-Thibault I, et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 2011;87:57-64.
35. Cha PC, Mushiroda T, Takahashi A, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2011;19:4735-44.
36. Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008;112:1022-7.
37. Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 2008;100:229-39.
38. Palareti G, Legnani C, Guazzaloca G, et al. Risks factors for highly unstable response to oral anticoagulation: a casecontrol study. Br J Haematol 2005;129:72-8. (Pubitemid 40524054)
39. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome P450 2C9 genotype. Thromb Haemost 2005;93:700-5. (Pubitemid 40485406)
40. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-19. (Pubitemid 29103806)
41. Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008;83:312-21.
42. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000;84:775-8.
43. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005;7:97-104. (Pubitemid 40261834)
44. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008;358:999-1008. (Pubitemid 351347099)
45. Limdi NA, Beasley TM, Crowley MR, et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 2008;9:1445-58.
46. Caldwell MD, Berg RL, Zhang KQ, et al. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 2007;5:8-16. (Pubitemid 350218774)
47. Lee MT, Chen CH, Chou CH, et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 2009;10:1905-13.
48. Kim HS, Lee SS, Oh M, et al. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenet Genomics 2009;19:103-12.
49. Owen RP, Altman RB, Klein TE. PharmGKB and the international warfarin pharmacogenetics consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics. Hum Mutat 2008;29:456-60. (Pubitemid 351536983)
50. Schelleman H, Chen J, Chen Z, et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African-Americans. Clin Pharmacol Ther 2008;84:332-9.
51. Lambert CA, Tishkoff SA. Genetic structure in African populations: implications of human demographic history. Cold Spring Harb Symp Quant Biol 2009;74:395-402.
52. Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH. Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 2007;8:1535-44. (Pubitemid 350286397)
53. Marsh S, King CR, Porche-Sorbet RM, Scott-Horton TJ, Eby CS. Population variation in VKORC1 haplotype structure. J Thromb Haemost 2006;4:473-4.
54. Voora D, Koboldt DC, King CR, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African-Americans. Clin Pharmacol Ther 2010;87:445-51.
55. Cavallari LH, Momary KM, Patel SR, Shapiro NL, Nutescu E, Viana MA. Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol Dis 2011;46:147-50.
56. Bristol-Myers Squibb. Coumadin (warfarin sodium) package insert. Princeton, NJ; 2010.
57. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 2006;95:782-7.
58. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006;16:101-10. (Pubitemid 43145678)
59. Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 2010;87:572-8.
60. Wu AH, Wang P, Smith A, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008;9:169-78. (Pubitemid 351566941)
61. Zambon CF, Pengo V, Padrini R, et al. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics 2011;12:15-25.
62. Sagreiya H, Berube C, Wen A, et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics 2010;20:407-13.
63. Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol 2011;57:612-18.
64. Shin J, Kayser SR. Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort. Pharmacotherapy 2011;31:863-70.
65. Langley MR, Booker JK, Evans JP, McLeod HL, Weck KE. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn 2009;11:216-25.
66. Roper N, Storer B, Bona R, Fang M. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn 2010;12:283-91.
67. Shin J, Cao D. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics 2011;12:125-34.
68. Shaw PB, Donovan JL, Tran MT, Lemon SC, Burgwinkle P, Gore J. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. J Thromb Thrombolysis 2010;30:220-5.
69. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007;116:2563-70. (Pubitemid 350179221)
70. Schwartz JB, Kane L, Moore K, Wu AH. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin [published online ahead of print January 24, 2011]. J Am Med Dir Assoc. Available from http://www.ncbi.nlm.nih.gov/pubmed/21450231.
71. Kadafour M, Haugh R, Posin M, Kayser SR, Shin J. Survey on warfarin pharmacogenetic testing among anticoagulation providers. Pharmacogenomics 2009;10:1853-60.
72. Meckley LM, Neumann PJ. Personalized medicine: factors influencing reimbursement. Health Policy 2009;94:91-100.
73. Ginsburg GS, Voora D. The long and winding road to warfarin pharmacogenetic testing. J Am Coll Cardiol 2010;55:2813-15.
74. McWilliam A, Lutter R, Nardinelli C. Health care savings from personalizing medicine using genetic testing: the case of warfarin 2006. Available from http://regulation2point0.org/wp-content/uploads/downloads/2010/ 04/WP06-23-topost.pdf. Accessed May 28, 2011.
75. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009;150:73-83.
76. You JH, Tsui KK, Wong RS, Cheng G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotypeguided dosing in patients starting warfarin therapy. Clin Pharmacol Ther 2009;86:540-7.
77. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 2010;28:61-74.
78. Leey JA, McCabe S, Koch JA, Miles TP. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. Am J Geriatr Pharmacother 2009;7:197-203.
79. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2009;2:429-36.
80. Centers for Disease Control and Prevention. Genomic testing, December 28, 2010. Available from http://www.cdc.gov/ genomics/gtesting/ACCE/. Accessed May 28, 2011.
81. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008;83:460-70. (Pubitemid 351272635)
82. Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 2009;19:226-34.
83. Burmester JK, Berg RL, Yale SH, et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med 2011;13:509-18.
84. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo warfarin effectiveness study). J Am Coll Cardiol 2010;55:2804-12.
85. National Heart, Lung, and Blood Institute. Clarification of optimal anticoagulation through genetics (COAG). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/ NCT00839657?term=clarification+optimal+anticoagulation+genetics&rank=1. Accessed March 14, 2011.
86. Washington University School of Medicine. Genetics informatics trial (GIFT) of warfarin to prevent DVT. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/ NCT01006733?term=genetics+informatics+trial&rank=1. Accessed March 14, 2011.
87. University of Chicago. Clinical and economic implications of genetic testing for warfarin management. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/ NCT00964353?term=clinical+economic+implication+of+genetic+testing&rank=1. Accessed March 14, 2011.
88. Utrecht Institute for Pharmaceutical Sciences. European pharmacogenetics of anticoagulation therapy - warfarin (EUPACT). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/ show/NCT01119300?term=european+pharmacogenetics+of+anticoagulation&rank=1. Accessed March 14, 2011.
89. French B, Joo J, Geller NL, et al. Statistical design of personalized medicine interventions: the clarification of optimal anticoagulation through genetics (COAG) trial [online exclusive article]. Trials 2010;11:108. Available from http://www.trialsjournal.com/content/11/1/108.
90. Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 2011;89:464-7.
91. Frith MC, Hansen U, Weng Z. Detection of cis-element clusters in higher eukaryotic DNA. Bioinformatics 2001;17:878-89. (Pubitemid 32998624)
92. Wingender E, Chen X, Hehl R, et al. TRANSFAC: an integrated system for gene expression regulation. Nucleic Acids Res 2000;28:316-19. (Pubitemid 30047792)
93. Perera MA, Thirumaran RK, Cox NJ, et al. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African-Americans. Pharmacogenomics J 2009;9:49-60.
94. Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A 2010;107:9287-92.
95. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99. (Pubitemid 351185753)
96. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95. (Pubitemid 351508116)
97. Stangier J, Rathgen K, Stahle H, Reseski K, Kornicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 2009;9:59-68.
98. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009;15(suppl 1):S9-16.
99. Chinn LW, Kroetz DL. ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther 2007;81:265-9. (Pubitemid 46174824)
100. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40. (Pubitemid 41262337)
101. Ufer M. Comparative efficacy and safety of the novel anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010;103:572-85.